Bedaquiline for the treatment of multidrug-resistant tuberculosis: Great promise or disappointment?

Therapeutic Advances in Chronic Disease

Volumn 6, Issue 4, 2015, Pages 170-184

  Field, Stephen K ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Bedaquiline; Diarylquinoline; Extensively drug resistant; Multidrug resistance; Mycobacterium tuberculosis; Tuberculosis

Indexed keywords

BEDAQUILINE; BENZOTHIAZINE DERIVATIVE; BENZOTHIAZINONE DERIVATIVE; BTZ 043; CLOFAZIMINE; DELAMANID; ETHYLENEDIAMINE DERIVATIVE; ISONIAZID; LINEZOLID; MOXIFLOXACIN; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; NITROIMIDAZOLE DERIVATIVE; PBTZ 169; POSIZOLID; PRETOMANID; PYRAZINAMIDE; RIFAMPICIN; RIFAPENTINE; SUTEZOLID; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTHRALGIA; BACTERIAL LOAD; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; COLONY FORMING UNIT; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; HEADACHE; HEMOPTYSIS; HUMAN; HYPERURICEMIA; LATENT TUBERCULOSIS; LOADING DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NAUSEA; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; THORAX PAIN; TREATMENT RESPONSE; UNILATERAL HEARING LOSS; VOMITING;

EID: 84930806540     PISSN: 20406223     EISSN: 20406231     Source Type: Journal    
DOI: 10.1177/2040622315582325     Document Type: Review

References (78)

1. Adams K. Szumowski J. Ramakrishnan L. (2014) Verapamil and its metabolite norverapamil, inhibit macrophage-induced, bacterial efflux pump-mediated tolerance to multiple anti-tubercular drugs. J Infect Dis 210: 456–466.
2. Andries K. Gevers T. Lounis N. (2010) Bactericidal potencies in a murine model of tuberculosis. Antimicrob Agents Chemother 54:4540–4544.
3. Andries K. Verhasselt P. Guillemont J. Gohlmann H. Neefs J. Winkler H. et al. (2005) A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307: 223–227.
4. Andries K. Villellas C. Coeck N. Thys K. Gevers T. Vranckx L. et al. (2014) Acquired resistance of Mycobacterium tuberculosis to bedaquiline. PloS ONE 9: e102135.
5. Avorn J. (2013) Approval of a tuberculosis drug based on a paradoxical surrogate measure. JAMA 309: 1349–1350.
6. Burman W. Cohn D. Rietmeijer C. Judson F. Sbarbaro J. Reves R. (1997) Noncompliance with directly observed therapy for tuberculosis: epidemiology and effect on the outcome of treatment. Chest 111: 1168–1173.
7. CDC (2013) Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis. MMWR Recomm Rep 62 (RR-090: 1–12).
8. Chan B. Khadem T. Brown J. (2013) A review of tuberculosis: focus on bedaquiline. Am J Health-Syst Pharm 70: 1984–1994.
9. Conradie F. Meintjes G. Hughes J. Maartens G. Ferreira H. Siwendu S. et al. (2014) Clinical access to bedaquiline programme for the treatment of drug-resistant tuberculosis. S Afr Med J 104: 164–166.
10. Cox E. Laessig K. (2014) FDA approval of bedaquiline – the benefit–risk balance for drug-resistant tuberculosis. New Engl J Med 371: 689–691.
11. de Jonge M. Koymans L. Guillemont J. Koul A. Andries K. (2007) A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910. Proteins 67: 971–980.
12. Dhillon J. Andries K. Phillips P. Mitchison D. (2010) Bactericidal activity of the diarylquinoline TMC 207 against Mycobacterium tuberculosis outside and within cells. Tuberculosis (Edinb) 90: 301–305.
13. Diacon A. Dawson R. von Groote-Bidlingmaier F. Symons G. Venter A. Donald P. et al. (2012 a) 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomized trial. Lancet 380 (9846): 986–993.
14. Diacon A. Dawson R. von Groote-Bidlingmaier F. Symons G. Venter A. Donald P. et al. (2013 a) Randomized dose-ranging study of the 14-day early bactericidal activity of bedaquiline (TMC207) in patients with sputum microscopy smear-positive pulmonary tuberculosis. Antimicrob Agents Chemother 57: 2199–2203.
15. Diacon A. Donald P. Pym A. Grobusch M. Patientia R. Mahanyele R. et al. (2012 b) Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother 56: 3271–3276.
16. Diacon A. Grosset J. Ammerman N. (2013 b) Dose-ranging activity of the newly registered antituberculosis drug bedaquiline (TMC207). Expert Rev Anti Infect Ther 11: 649–651.
17. Diacon A. Pym A. Grobusch M. Patientia R. Rustomjee R. Page-Shipp L. et al. (2009) The diarylquinoline TMC 207 for multidrug-resistant tuberculosis. New Engl J Med 360: 2397–2405.
18. Diacon A. Pym A. Grobusch M. de los Rios J. Gotuzzo E. Vasilyeva I. et al. (2014) Multidrug-resistant tuberculosis and culture conversion with bedaquiline. New Engl J Med 371: 723–732.
19. Dooley K. Park J. Swindells S. Allen R. Haas D. Cramer Y. et al. (2012) Safety, tolerability, and pharmacokinetic interactions of the antituberculosis agent TMC 207(bedaquiline) with efavirenz in healthy volunteers: AIDS clinical trials group. J AIDS 59: 455–462.
20. European Centre for Disease Prevention and Control (2012) Management of Contacts of MDR TB and XDR TB Patients. Stockholm: ECDC.
21. Gelber R. Andries K. Paredes R. Andaya C. Burgos J. (2009) The diarylquinoline R 207910 is bactericidal against Mycobacterium leprae in mice at low dose and administered intermittently. Antimicrob Agents Chemother 53: 3989–3991.
22. Gras J. (2013) Bedaquiline for the treatment of pulmonary, multidrug-resistant tuberculosis in adults. Drugs Today (BARC) 49: 353–361.
23. Guglielmetti L. Le Du D. Jachym M. Henry B. Martin D. Caumes E. et al. (2015) Compassionate use of bedaquiline for the treatment of MDR- and XDR-tuberculosis: an interim analysis of a French cohort. Clin Infect Dis 60: 188–194.
24. Gupta S. Cohen K. Winglee K. Maiga M. Diarra B. Bishai W. (2014 a) Efflux inhibition with verapamil potentiates bedaquiline in Mycobacterium tuberculosis. Antimicrob Agents Chemother 58: 574–576.
25. Gupta S. Tyagi S. Bishai W. (2014 b) Verampamil increases the bactericidal activity of bedaquiline against Mycobacterium tuberculosis in the mouse model. Anitmicrob Agents Chemother 59: 673–676.
26. Haagsma A. Abdilla-Ibrahim R. Wagner M. Krab K. Vergauwen K. Guillemont J. et al. (2009) Selectivity of TMC 207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue. Antimicrob Agents Chemother 53:1290–1292.
27. Haagsma A. Podasca I. Koul A. Andries K. Guillemont J. Lill H. et al. (2011) Probing the interaction of the diarylquinoline TMC 207 with its target mycobacterial ATP synthase. PloS ONE 6: e23575.
28. Hartkoorn R. Uplekar S. Cole S. (2014) Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL 5 in Mycobacterium tuberculosis. Antimicrob Agents Chemother 58:2979–2981.
29. Huitric E. Verhasselt P. Andries K. Hoffner S. (2007) In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother 51: 4202–4204.
30. Huitric E. Verhasselt P. Koul A. Andries K. Hoffner S. Andersson D. (2010) Rates and mechanisms of resistance development in Mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother 54: 1022–1028.
31. Ibrahim M. Andries K. Lounis N. Chaffour A. Truffot-Pernot C. Jarlier V. et al. (2007) Synergistic activity of R 207910 combined with pyrazinamide against murine tuberculosis. Antimicrob Agents Chemother 51: 1011–1015.
32. Ibrahim M. Truffot-Pernot C. Andries K. Jarlier V. Veziris N. (2009) Sterilizing activity of R 207910 (TMC207)-containing regimens in the murine model of tuberculosis. Am J Respir Crit Care Med 180: 553–557.
33. Iseman M. (1993) Treatment of multidrug-resistant tuberculosis. New Engl J Med 329: 784–794.
34. Janssen Therapeutics (2012) Sirturo (bedaquiline) product information. Available at: http://www.sirturo.com/sites/default/files/pdf/SIRTURO-product-guide.pdf (accessed 14 April 2015).
35. Ji B. Chauffour A. Andries K. Jarlier V. (2006 a) Bactericidal activities of R 207910 and other newer antimicrobial agents against Mycobacterium leprae in mice. Antimicrob Agents Chemother 50: 1558–1560.
36. Ji B. Lefrancois S. Robert J. Chauffour A. Truffot C. Jarlier V. (2006 b) In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans. Antimicrob Agents Chemother 50: 1921–1926.
37. Koul A. Dendouga N. Vergauwen K. Molenberghs B. Vranckx L. Willebrords R. et al. (2007) Diarylquinolines target subunit C of mycobacterial synthase. Nat Chem Biol 3: 323–324.
38. Koul A. Vranckx L. Dendouga N. Balemans W. van den Wyngart I. Vergauwen K. et al. (2008) Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J Biol Chem 283: 25273–25280.
39. Koul A. Vranckx L. Dhar N. Gohlmann H. Ozdemir E. Neefs J. et al. (2014) Delayed bactericidal response of Mycobacterium tuberculosis to bedaquiline involves remodelling of bacterial metabolism. Nat Commun 5: 3369.
40. Lanoix J. Betoudji F. Nuermberger E. (2014) Novel regimens identified in mice for treatment of latent tuberculosis infection in contacts of patients with multidrug-resistant tuberculosis. Antimicrob Agents Chemother 58: 2316–2321.
41. Lechartier B. Hartkoorn R. Cole S. (2012) In vitro combination studies of the benzothiazinone lead compound BTZ 043 against Mycobacterium tuberculosis. Antimicrob Agents Chemother 56: 5790–5793.
42. Lerat I. Cambau E. Roth dit Bettoni R. Jarlier V. Truffot C. Veziris N. (2014) In vivo evaluation of antibiotic activity against Mycobacterium abscessus. J Infect Dis 209: 905–912.
43. Liu K. Li F. Lu J. Liu S. Dorko K. Xie W. et al. (2014) Bedaquiline metabolism: enzymes and novel metabolites. Drug Metab Dispos 42:863–866.
44. Loddenkemper R. Sotgiu G. Mitnick C. (2012) Editorial. Cost of tuberculosis in the era of multidrug resistance: will it become unaffordable? Eur Respir J 40: 9–11.
45. Lounis N. Gevers T. van den Berg J. Andries K. (2008) Impact of the interaction of R 207910 with rifampin on the treatment of tuberculosis studied in the mouse model. Antimicrob Agents Chemother 52: 3568–3572.
46. Lounis N. Gevers T. van den Berg J. Vranckx L. Andries K. (2009) ATP synthase inhibition of Mycobacterium avium is not bactericidal. Antimicrob Agents Chemother 53: 4927–4929.
47. Lounis N. Veziris N. Chauffour A. Truffot-Pernot C. Andries K. Jarlier V. (2006) Combinations of R 207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration. Antimicrob Agents Chemother 50: 3543–3547.
48. Makarov K. Lechartier B. Zhang M. Neres J. van der Sar A. Raadsen S. et al. (2014) Towards a new combination therapy for tuberculosis with next generation benzothiazinones. EMBO Mol Med 6: 372–383.
49. McLeay S. Vis P. van Heeswijk R. van Heeswijk R. Green B. (2014) Population pharmacokinetics of bedaquiline (TMC207), a novel antituberculosis drug. Antimicrob Agents Chemother 58: 5315–5324.
50. Mitchison D. (2000) Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc Lung Dis 4: 796–806.
51. Petrella S. Cambau E. Chaffour A. Andries K. Jarlier V. Sougakoff W. (2006) Genetic basis for natural and acquired resistance to the diarylquinoline R 207910 in mycobacteria. Antimicrob Agents Chemother 50: 2853–2856.
52. Philley J. Wallace R. Jr Benwill J. Taskar V. Brown-Elliott B. Thakkar F. et al. (2015) Preliminary results of bedaquiline as salvage therapy for patients with nontuberculous mycobacterial lung disease. Chest On line 12 February 2015 (epub ahead of print).
53. Pooran A. Pieterson E. Davids M. Theron G. Dheda K. (2013) What is the cost of diagnosis and management of drug resistant tuberculosis in South Africa? PloS ONE 8: e54587.
54. Reddy V. Einck L. Andries K. Nacy C. (2010) In vitro interactions between new antitubercular drug candidates SQ 109 and TMC207. Antimicrob Agents Chemother 54: 2840–2846.
55. Rouan M. Lounis N. Gevers T. Dillen L. Gilissen R. Raoof A. et al. (2012) Pharmacokinetics and pharmacodynamics of TMC 207 and its N-desmethyl metabolite in a murine model of tuberculosis. Antimicrob Agents Chemother 56: 1444–1451.
56. Rustomjee R. Diacon A. Allen J. Venter A. Reddy C. Patientia R. et al. (2008) Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC 207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother 52: 2831–2835.
57. Segala E. Sougakoff W. Nevejans-Chaffour A. Jarlier V. Petrella S. (2012) New mutations in the mycobacterial ATP synthase: new insights into the binding of the diarylquinoline TMC 207 to the ATP synthase C-ring structure. Antimicrob Agents Chemother 56: 2326–2334.
58. Shang S. Shanley C. Caraway M. Orme E. Henao-Tamayo M. Hascall-Dove L. et al. (2011) Activities of TNC 207, rifampin, and pyrazinamide against Mycobacterium tuberculosis infection in guinea pigs. Antimicrob Agents Chemother 55: 124–131.
59. Svensson E. Aweeka F. Park J. Marzan F. Dooley K. Karlsson M. (2013) Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients co-infected with HIV and tuberculosis. Antimicrob Agents Chemother 57: 2780–2787.
60. Svensson E. Dooley K. Karlsson M. (2014 a) Impact of lopinavir / ritonavir or nevirapine on bedaquiline exposures: potential implications for patients with TB / HIV coinfection. Antimicrob Agents Chemother 11 August 2014 (epub ahead of print).
61. Svensson E. Murray S. Karlsson M. Dooley K. (2014 b) Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug. J Antimicrob Chemother 21 December 2014 (epub ahead of print).
62. Tasneen R. Li S. Peloquin C. Taylor D. Williams K. Andries K. et al. (2011) Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob Agents Chemother 55: 5485–5492.
63. US FDA (2012) Center for drug evaluation and research. Application number: 204384Orig1S000. Clinical review bedaquiline. Available at: www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=search.label_approvalhistory#apphist (accessed 20 October 2014).
64. Veziris N. Ibrahim M. Lounis N. Andries K. Jarlier V. (2011) Sterilizing activity of second-line regimens containing TMC 207 in a murine model of tuberculosis. PloS ONE 6: e17556.
65. Veziris N. Ibrahim M. Lounis N. Chaffour A. Truffot-Pernot C. Andries K. et al. (2009) A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis. Am J Respir Crit Care Med 179: 75–79.
66. Wallis R. Jakubiec W. Mitton-Fry M. Ladutko L. Campbell S. Paige D. et al. (2012) Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide. PloS ONE 7: e30479.
67. WHO (2010 a) Treatment of Tuberculosis: Guidelines (4th edition). WHO/HTM/TB/2009.420. Available at: http://whqlibdoc.who.int/publications/2010/9789241547833_eng.pdf?ua=1 (accessed 14 April 2015).
68. WHO (2010 b) Media Centre. Drug-resistant Tuberculosis Now at Record Levels. Geneva, March 18, 2010. Available at: http://www.who.int/mediacentre/news/releases/2010/drug_resistant_tb (accessed 20 October 2014).
69. WHO (2011) Guidelines for the Programmatic Management of Drug-resistant Tuberculosis. Available at: http://www.who.int/tb/publications/2011/en/index.html (accessed 14 April 2015).
70. WHO (2013 a) The Use of Bedaquiline in that Treatment of Multidrug-resistant Tuberculosis. Interim Policy Guidance. Available at: http://apps.who.int/iris/bitstream/10665/75146/1/9789241548441_eng.pdf (accessed 14 April 2015).
71. WHO (2013 b) Global Tuberculosis Report, 2013. Available at: http://apps.who.int/iris/bitstream/10665/91355/1/9789241564656_eng.pdf (accessed 21 September 2014).
72. WHO (2014 a) Global Tuberculosis Report 2014. Available at: http://www.who.int/tb/publications/global_report/gtbr14_main_text.pdf?ua=11 (accessed 22 October 2014).
73. WHO (2014 b) Companion Handbook to the WHO Guidelines for the Programmic Management of Drug-resistant Tuberculosis. Available at: http://apps.who.int/iris/bitstream/10665/130918/1/97892241548809_eng.pdf?ua=1 (accessed 2 October 2014).
74. Williams K. Minkowski A. Amoabeng O. Peloquin C. Taylor D. Andries K. et al. (2012) Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother 56: 3114–3120.
75. Working Group on New TB Drugs (2014) TB Drug Pipeline, August 2014. Available at: http://www.newtbdrugs.org/downloads/pipeline-slide/WGND_Global_TB_Drug_and_Discovery_Pipelines-AUG2014.ppt (accessed 31 October 2014).
76. Zhang M. Sala C. Hartkoorn R. Dhar N. Mendoza-Losana A. Cole S. (2012) Streptomycin-starved Mycobacterium tuberculosis 18b, a drug discovery tool for latent tuberculosis. Antimicrob Agents Chemother 56: 5782–5789.
77. Zhang T. Li S. Williams K. Andries K. Nuermberger E. (2011) Short-course chemotherapy with TMC 207 and rifapentine in a murine model of latent tuberculosis infection. Am J Respir Crit Care Med 184: 732–737.
78. Zhang Y. Mitchison D. (2003) The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis 7: 6–21.